Q1 EPS Forecast for Oncolytics Biotech Lifted by Analyst

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Equities research analysts at HC Wainwright upped their Q1 2026 EPS estimates for Oncolytics Biotech in a research note issued on Friday, April 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.03) per share for the quarter, up from their prior forecast of ($0.06). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.12) EPS, FY2027 earnings at ($0.07) EPS, FY2028 earnings at ($0.08) EPS and FY2029 earnings at ($0.07) EPS.

Oncolytics Biotech (NASDAQ:ONCY) last posted its earnings results on Monday, March 30th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02).

Several other equities analysts have also issued reports on ONCY. Weiss Ratings reissued a “sell (e+)” rating on shares of Oncolytics Biotech in a research note on Friday, March 27th. Wall Street Zen raised Oncolytics Biotech from a “strong sell” rating to a “hold” rating in a research note on Saturday, April 4th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

Oncolytics Biotech Trading Up 12.9%

ONCY opened at $1.05 on Tuesday. The stock’s 50-day moving average price is $0.97 and its 200 day moving average price is $1.04. Oncolytics Biotech has a 12-month low of $0.33 and a 12-month high of $1.51. The firm has a market cap of $121.93 million, a price-to-earnings ratio of -3.62 and a beta of 0.98.

Institutional Investors Weigh In On Oncolytics Biotech

Hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new stake in Oncolytics Biotech in the 3rd quarter valued at about $535,000. XTX Topco Ltd acquired a new stake in Oncolytics Biotech in the 4th quarter valued at about $69,000. Virtu Financial LLC acquired a new stake in Oncolytics Biotech in the 4th quarter valued at about $68,000. Tocqueville Asset Management L.P. acquired a new stake in Oncolytics Biotech in the 4th quarter valued at about $63,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in Oncolytics Biotech in the 4th quarter valued at about $44,000. Institutional investors and hedge funds own 6.82% of the company’s stock.

Insider Transactions at Oncolytics Biotech

In other news, Director Bernd R. Seizinger bought 100,000 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The shares were purchased at an average price of $1.04 per share, with a total value of $104,000.00. Following the purchase, the director owned 466,991 shares in the company, valued at approximately $485,670.64. The trade was a 27.25% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Wayne Pisano bought 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The shares were purchased at an average cost of $0.84 per share, for a total transaction of $25,200.00. Following the purchase, the director owned 492,414 shares in the company, valued at $413,627.76. This represents a 6.49% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 404,282 shares of company stock worth $363,232 in the last 90 days. Insiders own 0.10% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard?of?care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non?small cell lung cancer and head and neck cancers.